Elacestrant Plus Abemaciclib Shows Efficacy in ER+/HER2– Advanced or Metastatic Breast Cancer
The combination of elacestrant (Orserdu) and abemaciclib (Verzenio) provided clinical benefit with acceptable safety in patients with estrogen receptor (ER)–positive/HER2-negative advance or metastatic breast cancer with prior exposure to endocrine …